Revolution Medicines (NASDAQ:RVMD) Earns "Buy" Rating from Stifel Nicolaus

Key Points

• Stifel Nicolaus reiterated a Buy rating and raised its price target to $215 (from $170), implying roughly a 42% upside from the current share price.
• Revolution Medicines opened at $151.24 with a market cap of about $29.97 billion and a 12‑month high of $155.70, but remains unprofitable—last quarter EPS was -$1.86 and analysts forecast roughly -$3.49 for the fiscal year.
• Significant insider selling has occurred recently: Mark A. Goldsmith sold 120,000 shares for about $18.0 million, and insiders sold ~184,592 shares (~$24.5 million) over the past three months, leaving insiders with ~8.2% ownership.

Revolution Medicines (NASDAQ:RVMD - Get Free Report)'s stock had its "buy" rating restated by research analysts at Stifel Nicolaus in a research note issued to investors on Monday,Benzinga reports. They currently have a $215.00 price target on the stock, up from their previous price target of $170.00. Stifel Nicolaus' price objective would indicate a potential upside of 42.16% from the stock's current price.

Several other analysts also recently issued reports on the company. UBS Group started coverage on Revolution Medicines in a report on Friday, February 27th. They issued a "buy" rating for the company. Jefferies Financial Group began coverage on shares of Revolution Medicines in a research report on Monday, March 16th. They issued a "buy" rating for the company. Truist Financial upgraded Revolution Medicines to a "strong-buy" rating in a research note on Wednesday, March 25th. Evercore reiterated an "outperform" rating on shares of Revolution Medicines in a research note on Tuesday, April 14th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Revolution Medicines in a report on Thursday, January 22nd. Four research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Revolution Medicines has a consensus rating of "Buy" and an average target price of $86.59.

Revolution Medicines Price Performance

Shares of NASDAQ:RVMD opened at $151.24 on Monday. The firm has a market capitalization of $29.97 billion, a price-to-earnings ratio of -25.63 and a beta of 1.01. Revolution Medicines has a 12 month low of $34.00 and a 12 month high of $155.70. The company has a debt-to-equity ratio of 0.16, a current ratio of 7.14 and a quick ratio of 7.14. The business's 50 day simple moving average is $103.12 and its 200-day simple moving average is $86.47.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last posted its quarterly earnings data on Wednesday, February 25th. The company reported ($1.86) EPS for the quarter, missing analysts' consensus estimates of ($1.56) by ($0.30). During the same quarter in the prior year, the business earned ($1.12) EPS. As a group, equities analysts forecast that Revolution Medicines will post -3.49 earnings per share for the current fiscal year.

Insider Transactions at Revolution Medicines

In related news, insider Stephen Michael Kelsey sold 4,302 shares of the stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $99.48, for a total value of $427,962.96. Following the sale, the insider owned 295,398 shares of the company's stock, valued at $29,386,193.04. This trade represents a 1.44% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Mark A. Goldsmith sold 120,000 shares of the firm's stock in a transaction that occurred on Wednesday, April 15th. The shares were sold at an average price of $150.09, for a total value of $18,010,800.00. Following the completion of the sale, the insider owned 276,698 shares in the company, valued at approximately $41,529,602.82. This represents a 30.25% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 184,592 shares of company stock valued at $24,499,532 over the last three months. 8.20% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Revolution Medicines

A number of hedge funds and other institutional investors have recently modified their holdings of RVMD. PKO Investment Management Joint Stock Co bought a new position in Revolution Medicines in the 1st quarter valued at about $146,000. SG Americas Securities LLC grew its stake in shares of Revolution Medicines by 219.5% in the 1st quarter. SG Americas Securities LLC now owns 53,426 shares of the company's stock worth $5,196,000 after purchasing an additional 36,703 shares during the last quarter. E. Ohman J or Asset Management AB acquired a new position in Revolution Medicines in the first quarter worth approximately $389,000. BI Asset Management Fondsmaeglerselskab A S bought a new position in shares of Revolution Medicines in the first quarter valued at $452,000. Finally, Rockefeller Capital Management L.P. increased its holdings in shares of Revolution Medicines by 82.9% in the fourth quarter. Rockefeller Capital Management L.P. now owns 598 shares of the company's stock valued at $48,000 after buying an additional 271 shares in the last quarter. 94.34% of the stock is currently owned by institutional investors.

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company's research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.